BMRA
HEALTHCAREBiomerica Inc
Live · NASDAQ · May 9, Close
What's Moving BMRA Today?
No stock-specific AI insight has been generated for BMRA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.21
Fundamentals
Trading
BMRA News
20 articles- Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026Yahoo Finance·Apr 29, 2026
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization PathwayYahoo Finance·Apr 16, 2026
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health LabsYahoo Finance·Apr 14, 2026
- Biomerica Reports Third Quarter Fiscal 2026 Financial ResultsYahoo Finance·Apr 13, 2026
- Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in EuropeYahoo Finance·Mar 18, 2026
- Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great BritainYahoo Finance·Mar 5, 2026
- Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS TherapyYahoo Finance·Feb 26, 2026
- Vietnam Approves Biomerica’s EZ Detect™ for Nationwide DistributionYahoo Finance·Feb 18, 2026
- Biomerica Reports Second Quarter Fiscal 2026 Financial ResultsYahoo Finance·Jan 14, 2026
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS TestYahoo Finance·Dec 23, 2025
- Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test PortfolioYahoo Finance·Dec 11, 2025
- Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBSYahoo Finance·Nov 25, 2025
- Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market DemandYahoo Finance·Nov 6, 2025
- How Biomerica Deal Expands Henry Schein’s (HSIC) Diagnostic Ambitions and Alters Its Investment NarrativeYahoo Finance·Oct 17, 2025
- Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.Yahoo Finance·Oct 16, 2025
- Biomerica Reports First Quarter Fiscal 2026 Financial ResultsYahoo Finance·Oct 15, 2025
- Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of DirectorsYahoo Finance·Oct 8, 2025
- Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient OutcomesYahoo Finance·Sep 9, 2025
- United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home UseYahoo Finance·Sep 3, 2025
- Biomerica Reports Fiscal 2025 Year End ResultsYahoo Finance·Aug 29, 2025
All 20 articles loaded
Price Data
52-Week Range
$2.21
Fundamentals
Trading
About Biomerica Inc
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology company specializing in the development and manufacturing of cutting-edge diagnostic solutions across the medical and food sectors. With a strong focus on proprietary testing methods for managing metabolic diseases, gastrointestinal disorders, and food intolerances, Biomerica is committed to improving healthcare outcomes. The company actively engages in strategic research collaborations, positioning itself to address critical unmet medical needs and harness growth opportunities in the rapidly evolving diagnostics landscape. Leveraging technological advancements and a patient-centered approach, Biomerica is well-positioned to lead transformational changes in global healthcare diagnostics.